ORGANOIDSCIENCES

476040 · KQ · Healthcare / Biotechnology

4,960.00KRW-40.00 (-0.80%)

Price History

Full chart

Market Stats

Previous Close5,000.00

Open5,020.00

Day Range4,955.00 – 5,320.00

52-Week Range6,070.00 – 48,500.00

Volume13.74K

Market Cap46.50B

P/E (TTM)0.00

Forward P/E0.00

Dividend Yield0.00%

50-Day Avg7,190.20

200-Day Avg19,612.05

About

Organoidsciences Ltd. develops regenerative therapies in South Korea. It develops ATORM, an adult tissue derived organoid based regenerative medicine platform for the treatment of intractable intestinal ulcers, as well as salivary glands, liver, and uterus disease areas; ODISEI solutions, an organoid-based discovery platform for screening evaluation and identification; and EXPANSION, an organoid-based advanced science for innovative solutions. The company was founded in 2018 and is based in Seongnam-si, South Korea.

Company Details

SectorHealthcare
IndustryBiotechnology
CEOJong-Man Yoo
Employees76
Headquarters338 Pangyo-ro, Seongnam-si, South Korea, 13488, Korea
Websitehttps://organoidrx.com

Leadership

Jong-Man YooChief Executive Officer
Jinman HongChief Financial Officer
Dong-Youn HwangCSO, Senior Managing Director & Head of Organoidsciences Future Innovative Tech. HQ
Yang Seung-hyeChief Medical Officer
Donghyun KimHead of Manufacturing Headquarters

Financials

Income Statement

Currency: KRW	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	270.25M	438.24M	1.59B	1.95B	2.41B
Growth (%)	-	+62.16%	+263.05%	+22.77%	+23.21%
Gross Profit	270.25M	438.24M	1.59B	1.95B	2.41B
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Expense	4.98B	10.99B	11.35B	14.19B	18.61B
Operating Income	-4.71B	-10.55B	-9.76B	-12.23B	-16.20B
Operating Margin	-1743.66%	-2407.94%	-613.66%	-626.38%	-673.16%
EBITDA	-	-18.40B	-31.73B	-7.04B	-13.93B
EBITDA Margin	-	-4198.80%	-1994.41%	-360.51%	-578.87%
Net Income	-17.62B	-24.11B	-38.69B	-11.25B	-15.37B
Net Income Margin	-6518.04%	-5501.84%	-2431.56%	-575.78%	-638.59%
R&D	2.94B	6.23B	4.78B	5.22B	6.61B
R&D as % of Total Revenue	1086.68%	1421.00%	300.18%	267.08%	274.50%
Interest Expense	1.07B	4.91B	5.99B	3.19B	363.32M
Interest Expense % of Total Revenue	395.86%	1119.47%	376.60%	163.31%	15.10%

Balance Sheet

Currency: KRW	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	37.28B	39.76B	32.76B	25.89B	37.19B
Total Liabilities	53.24B	79.32B	110.09B	10.58B	12.35B
Total Equity	-15.96B	-39.56B	-77.34B	15.31B	24.66B
Cash	30.56B	5.00B	2.45B	1.95B	5.24B
Net Debt	-	-	-	3.75B	295.06M

Cash Flow

Currency: KRW	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-4.96B	-8.52B	-7.25B	-9.14B	-13.99B
Investing Cash Flow	-	-28.33B	4.60B	4.93B	-
Financing Cash Flow	-	11.29B	180.43M	3.66B	-
Capital Expenditure	3.93B	1.80B	1.02B	787.28M	1.96B
Free Cash Flow	-8.89B	-10.32B	-8.27B	-9.93B	-15.95B
FCF to OCF	179.29%	121.18%	114.05%	108.61%	114.04%

Earnings

Report Date	Jun 30, 2025	Sep 30, 2025	Dec 31, 2025	Mar 31, 2026	Jun 30, 2026
EPS Estimate	-	-	-	-	-
EPS Actual	-675.26	-577.08	-536.48	-669.58	-1052.16
Surprise	-	-	-	-	-
Timing	-	-	-	-	-

Key Statistics & Ratios

Market Cap46.50B

Enterprise Value24.54B

Trailing P/E0.00

Forward P/E0.00

Price / Sales20.31

Price / Book1.49

Revenue (TTM)2.29B

Gross Profit (TTM)2.23B

EBITDA-14.54B

Profit Margin0.00%

Operating Margin-728.19%

Return on Equity-62.29%

Return on Assets-20.16%

Shares Outstanding6.59M

Shares Float3.69M

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%